Gross Margin: 32.54%
Is the gross margin high or low?
The gross margin of 32.54% is in line with its 5-year average of 34.47%, near the low end of its 5-year range (32.34%–40.22%).
As of Friday, June 26, 2026. 1.70% below its 12-month average of 33.10%.
DGX Gross Margin
Reported quarterly gross margin; no daily interpolation.
DGX Average Gross Margin Chart
DGX Current vs Average Gross Margin Chart
DGX Gross Margin Metrics
GROSS MARGIN
32.54%
GROSS MARGIN AVG TTM
33.10%
GROSS MARGIN AVG 3Y
33.01%
GROSS MARGIN AVG 5Y
33.62%
GROSS MARGIN AVG 10Y
35.60%
GROSS MARGIN AVG 15Y
36.89%
GROSS MARGIN AVG 20Y
37.97%
CURRENT VS TTM AVG
-1.70%
CURRENT VS 3Y AVG
-1.42%
CURRENT VS 5Y AVG
-3.22%
CURRENT VS 10Y AVG
-8.61%
CURRENT VS 15Y AVG
-11.79%
CURRENT VS 20Y AVG
-14.29%
DGX Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated (DGX) | $22.83B | 32.54% | 33.10% | 33.01% | 33.62% |
| BioNTech SE (BNTX)vs › | $22.76B | 73.26% | 78.98% | 81.24% | 82.89% |
| United Therapeutics Corporation (UTHR)vs › | $23.07B | 86.58% | 88.58% | 89.63% | 90.66% |
| Moderna, Inc. (MRNA)vs › | $23.71B | -13.89% | 54.80% | 53.09% | 65.45% |
| Labcorp Holdings Inc. (LH)vs › | $21.83B | 27.79% | 27.30% | 28.39% | 31.16% |
| Incyte Corporation (INCY)vs › | $21.48B | 92.48% | 92.70% | 93.10% | 93.74% |
| Waters Corporation (WAT)vs › | $24.57B | 55.02% | 58.60% | 58.69% | 58.45% |
| Mettler-Toledo International Inc. (MTD)vs › | $25.13B | 57.79% | 57.84% | 57.54% | 57.23% |
| STERIS plc (STE)vs › | $20.52B | 44.25% | 44.13% | 43.77% | 43.82% |
| Veeva Systems Inc. (VEEV)vs › | $25.68B | 74.95% | 75.03% | 73.28% | 73.00% |
Gross Margin Analysis
Gross Margin
32.5%
(Revenue - COGS) / Revenue
Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Gross Margin FAQ
- What is the gross margin for Quest Diagnostics Incorporated (DGX)?
- The gross margin for DGX stock is 32.54%.
- Is Quest Diagnostics Incorporated's gross margin high or low?
- The gross margin of 32.54% is in line with its 5-year average of 34.47%, near the low end of its 5-year range (32.34%–40.22%).
- What is the TTM average gross margin for Quest Diagnostics Incorporated (DGX)?
- The TTM average gross margin for DGX stock is 33.10%.
- What is the 3Y average gross margin for Quest Diagnostics Incorporated (DGX)?
- The 3Y average gross margin for DGX stock is 33.01%.
- What is the 5Y average gross margin for Quest Diagnostics Incorporated (DGX)?
- The 5Y average gross margin for DGX stock is 33.62%.
- What is the 10Y average gross margin for Quest Diagnostics Incorporated (DGX)?
- The 10Y average gross margin for DGX stock is 35.60%.
- What is the 15Y average gross margin for Quest Diagnostics Incorporated (DGX)?
- The 15Y average gross margin for DGX stock is 36.89%.
- What is the 20Y average gross margin for Quest Diagnostics Incorporated (DGX)?
- The 20Y average gross margin for DGX stock is 37.97%.
DGX Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2026-03-31 | 32.54% |
| 2025-12-31 | 32.57% |
| 2025-09-30 | 33.70% |
| 2025-06-30 | 34.15% |
| 2025-03-31 | 32.54% |
| 2024-12-31 | 32.74% |
| 2024-09-30 | 32.60% |
| 2024-06-30 | 33.54% |
| 2024-03-31 | 32.59% |
| 2023-12-31 | 32.34% |
| 2023-09-30 | 32.85% |
| 2023-06-30 | 33.88% |
| 2023-03-31 | 33.08% |
| 2022-12-31 | 32.49% |
| 2022-09-30 | 34.92% |
| 2022-06-30 | 34.33% |
| 2022-03-31 | 36.96% |
| 2021-12-31 | 37.39% |
| 2021-09-30 | 39.80% |
| 2021-06-30 | 38.63% |
| 2021-03-31 | 40.22% |
| 2020-12-31 | 42.27% |
| 2020-09-30 | 43.29% |
| 2020-06-30 | 33.17% |
| 2020-03-31 | 30.30% |
| 2019-12-31 | 34.37% |
| 2019-09-30 | 35.38% |
| 2019-06-30 | 35.23% |
| 2019-03-31 | 34.21% |
| 2018-12-31 | 32.84% |
| 2018-09-30 | 35.31% |
| 2018-06-30 | 35.23% |
| 2018-03-31 | 34.93% |
| 2017-12-31 | 38.33% |
| 2017-09-30 | 38.37% |
| 2017-06-30 | 39.78% |
| 2017-03-31 | 38.65% |
| 2016-12-31 | 37.67% |
| 2016-09-30 | 38.62% |
| 2016-06-30 | 39.40% |
| 2016-03-31 | 38.59% |
| 2015-12-31 | 37.80% |
| 2015-09-30 | 38.19% |
| 2015-06-30 | 38.60% |
| 2015-03-31 | 36.76% |
| 2014-12-31 | 37.12% |
| 2014-09-30 | 38.13% |
| 2014-06-30 | 38.28% |
| 2014-03-31 | 36.94% |
| 2013-12-31 | 40.15% |
| 2013-09-30 | 39.09% |
| 2013-06-30 | 39.76% |
| 2013-03-31 | 38.89% |
| 2012-12-31 | 39.53% |
| 2012-09-30 | 41.14% |
| 2012-06-30 | 41.76% |
| 2012-03-31 | 42.34% |
| 2011-12-31 | 42.67% |
| 2011-09-30 | 41.43% |
| 2011-06-30 | 41.97% |
| 2011-03-31 | 39.78% |
| 2010-12-31 | 40.77% |
| 2010-09-30 | 41.47% |
| 2010-06-30 | 42.45% |
| 2010-03-31 | 40.94% |
| 2009-12-31 | 42.10% |
| 2009-09-30 | 42.15% |
| 2009-06-30 | 42.15% |
| 2009-03-31 | 41.73% |
| 2008-12-31 | 42.18% |
| 2008-09-30 | 41.25% |
| 2008-06-30 | 41.05% |
| 2008-03-31 | 40.68% |
| 2007-12-31 | 41.10% |
| 2007-09-30 | 41.90% |
| 2007-06-30 | 40.97% |
| 2007-03-31 | 38.95% |
| 2006-12-31 | 40.66% |
| 2006-09-30 | 41.02% |
| 2006-06-30 | 40.89% |
| 2006-03-31 | 40.66% |
| 2005-12-31 | 39.26% |
| 2005-09-30 | 41.17% |
| 2005-06-30 | 42.02% |
| 2005-03-31 | 40.88% |
| 2004-12-31 | 40.98% |
| 2004-09-30 | 41.98% |
| 2004-06-30 | 41.57% |
| 2004-03-31 | 41.29% |
| 2003-12-31 | 41.34% |
| 2003-09-30 | 41.76% |
| 2003-06-30 | 42.36% |
| 2003-03-31 | 40.69% |
| 2002-12-31 | 40.09% |
| 2002-09-30 | 40.96% |
| 2002-06-30 | 41.03% |
Related Metrics
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James E. Davis